

3.2 Zusammenfassung Publikationen (Google Scholar, ISI Web)	
Publikationen gesamt	192
Peer-reviewed Publikationen gesamt	185
Peer-reviewed Publikationen als Erst/Letztautor	102
Impact Factor aller Peer-reviewed Publikationen	IF 864.8
Zitate aller Peer-reviewed Publikationen	5971
Impact Factor Peer-reviewed Publikationen als Erst/Letztautor	IF 425.9
Zitate Peer-reviewed Publikationen als Erst/Letztautor	3146
Kapitel in Fachbüchern	7

Originalarbeiten in Peer-reviewed Journalen	124
Impact Factor Originalarbeiten in Peer-reviewed Journalen	IF 456.6
Zitate Originalarbeiten in Peer-reviewed Journalen	5711

Originalarbeiten in Peer-reviewed Journalen als Erst/Letztautor	60
Impact Factor Originalarbeiten in Peer-reviewed Journalen als Erst/Letztautor	IF 247.9
Zitate Originalarbeiten in Peer-reviewed Journalen als Erst/Letztautor	3108
H-Index	35

Bibliographie	

3.3.1 Original Publications in peer-reviewed Journals (IF taken from Journal Citation Reports, Thomson Reuters 2017)

1. Kristo I, Paireder M, Jomrich G, Felsenreich DM, Nikolic M, Langer FB, Prager G, Schoppmann SF.
Modern esophageal function testing and gastroesophageal reflux disease in morbidly-obese patients.
Obes Surg 2019 in press
IF 3.895
2. Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann SF.
High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma.
Ann Surg 2019 in press
IF 9.203, Cited 1 time.
3. Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Schoppmann SF.
High mean corpuscular volume predicts poor outcome for patients with gastroesophageal adenocarcinoma
Annals of Surgical Oncology 2019, 26 (4), pp. 976-985
IF 3.857, Cited 1 time.

4. Nikolic M, Schwameis K, Semmler G, Asari R, Semmler L, Steindl A, Mosleh BO, [Schoppmann SF](#).
Persistent dysphagia is a rare problem after laparoscopic Nissen fundoplication
Surgical Endoscopy 2019, 33 (4), pp. 1196-1205
IF 3.117
5. Paireder M, Kristo I, Asari R, Jomrich G, Steindl J, Rieder E, [Schoppmann SF](#).
Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility—a safety and efficacy study
Surgical Endoscopy 2019, Article in Press.
IF 3.117
6. Tamandl D, Fueger B, Haug A, Schmid R, Stift J, [Schoppmann SF](#), Ilhan-Mutlu A, Ba-Ssalamah A.
A diagnostic algorithm that combines quantitative 18 F-FDG PET parameters and contrast-enhanced CT improves posttherapeutic locoregional restaging and prognostication of survival in patients with esophageal cancer
Clinical Nuclear Medicine 2019, 44 (1), pp. e13-e21.
IF 6.309
7. Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, [Schoppmann SF](#).
Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study
European Surgery - Acta Chirurgica Austriaca 2018, 50 (6), pp. 249-255.
IF 0.349, Cited 1 time.
8. Kristo I, Schwameis K, Maschke S, Kainz A, Rieder E, Paireder M, Jomrich G, [Schoppmann SF](#).
Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
Scientific Reports 2018, 8 (1), art. no. 9949,
IF 4.122
9. Schwameis K, Nikolic M, Castellano DGM, Steindl A, Macheck S, Riegler M, Kristo I, Zörner B, [Schoppmann SF](#).
Crural closure improves outcomes of magnetic sphincter augmentation in GERD patients with hiatal hernia
Scientific Reports 2018, 8 (1), art. no. 7433,
IF 4.122, Cited 3 times.
10. Schwameis K, Nikolic M, Morales Castellano DG, Steindl A, Macheck S, Kristo I, Zörner B, [Schoppmann SF](#).
Results of Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease
World Journal of Surgery 2018, 42 (10), pp. 3263-3269.
IF 2.766, Cited 3 time.
11. Rieder E, Paireder M, Kristo I, Schwameis K, [Schoppmann SF](#).
Electrical Stimulation of the Lower Esophageal Sphincter to Treat Gastroesophageal Reflux After POEM
Surgical Innovation 2018, 25 (4), pp. 346-349.
IF 1.549
12. Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kühner I, Pluschnig U, [Schoppmann SF](#), Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D, Kandioler D, the Pancho trialists and for the Medical University of Vienna p53research group
Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected
European Surgery - Acta Chirurgica Austriaca 2018, 50 (4), pp. 160-166.
IF 0.349, Cited 2 times.
13. Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, [Schoppmann SF](#).
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
OncoImmunology 2018, 7 (6), art. no. e1435226,
IF 5.503, Cited 4 times.

14. Kristo I, Schwameis K, Paireder M, Jomrich G, Kainz A, [Schoppmann SF](#).
Dysphagia severity is related to the amplitude of distal contractile integral in patients with Jackhammer esophagus
Neurogastroenterology and Motility 2018, 30 (5), art. no. e13276,
IF 3.842, Cited 2 time.
15. Ilhan-Mutlu, A., Taghizadeh, H., Beer, A., Dolak, W., Ba-Ssalamah, A., [Schoppmann, S.F.](#), Hejna, M., Birner, P., Preusser, M.
Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
Cancer Biology and Therapy 2018, 19 (3), pp. 169-174.
IF 3.373, Cited 1 time.
16. Kristo I, Rieder E, Paireder M, Schwameis K, Jomrich G, Dolak W, Parzefall T, Riegler M, Asari R, [Schoppmann SF](#).
Radiofrequency ablation in patients with large cervical heterotopic gastric mucosa and globus sensation: Closing the treatment gap
Digestive Endoscopy 2018, 30 (2), pp. 212-218.
IF 3.375, Cited 2 times.
17. Arnoldner MA, Kristo I, Paireder M, Cosentini EP, Schima W, Weber M, [Schoppmann SF](#), Kulinna-Cosentini C.
Swallowing MRI—a reliable method for the evaluation of the postoperative gastroesophageal situs after Nissen fundoplication
European Radiology 2018, Nov 2018, Epub ahead of print
IF 4.027, Cited 1 time.
18. Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, [Schoppmann SF](#).
MK2 and ETV1 are prognostic factors in esophageal adenocarcinomas
Journal of Cancer 2018, 9 (3), pp. 460-468.
IF 3.249, Cited 2 times.
19. Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, [Schoppmann SF](#).
The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
Oncotarget 2018, 9 (6), pp. 6968-6976.
IF 5.168, Cited 4 times.
20. Paireder M, Jomrich G, Asari R, Kristo I, Gleiss A, Preusser M, [Schoppmann SF](#).
External validation of the NUn score for predicting anastomotic leakage after oesophageal resection
Scientific Repors 2017, Aug 29;7(1):9725
IF 4.122, Cited 2 time.
21. Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang Y-T, Lewik G, [Schoppmann SF](#), Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K.
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Oncoimmunology 2017, 6 (9), e1331194
IF 5.503, Cited 8 times.
22. Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, [Schoppmann SF](#).
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
Annals of Surgical Oncology 2017, 24 (9), pp. 2698-2706.
IF 3.857, Cited 7 times.
23. Ringhofer C, Lenglinger J, Riegler M, Kristo I, Kainz A, [Schoppmann SF](#).
Waist to hip ratio is a better predictor of esophageal acid exposure than body mass index
Neurogastroenterology and Motility 2017, 29 (7), art. no. e13033,
IF 3.842, Cited 5 times.

24. Prusa AM, Kristo I, Rieder E, Ringhofer C, Asari R, Miholic J, [Schoppmann SF](#).
Tension-Free Inlay Repair of Large Hiatal Hernias Using Dual-Sided Composite PTFE/ePTFE Meshes in Laparoscopic Surgery for Gastroesophageal Reflux Disease
Journal of Laparoendoscopic and Advanced Surgical Techniques 2017, 27 (7), pp. 710-714.
IF 1.257, Cited 3 time.
25. Rieder E, Asari R, Paireder M, Lenglinger J, [Schoppmann SF](#).
Endoscopic stent suture fixation for prevention of esophageal stent migration during prolonged dilatation for achalasia treatment
Diseases of the Esophagus 2017, 30 (4), pp. 1-6.
IF 2.702, Cited 3 times.
26. Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, [Schoppmann SF](#).
Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer
European Journal of Surgical Oncology 2017, 43 (2), pp. 478-484.
IF 3.688 Cited 28 times.
27. Jomrich G, Paireder M, Gleiss A, Kristo I, Harpain L, [Schoppmann SF](#).
Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer
Gastroenterology Research and Practice 2017, e1678584, .
IF 1.859, Cited 7 times.
28. Dolak W, Beer A, Kristo I, Tribl B, Asari R, Schöniger-Hekele M, Wrba F, [Schoppmann SF](#), Trauner M, Püspök A.
A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors
Gastrointestinal Endoscopy 2016, 84 (6), pp. 924-929.
IF 7.204, Cited 5 times.
29. Schiefer A-I, [Schoppmann SF](#), Birner P.
Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer
Surgery (United States) 2016, 160 (2), pp. 331-340.
IF 3.574, Cited 11 times.
30. Tamandl D, Paireder M, Asari R, Baltzer PA, [Schoppmann SF](#), Ba-Ssalamah A.
Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer
European Radiology 2016, 26 (5), pp. 1359-1367.
IF 4.027, Cited 76 times.
31. Tamandl D, Ta J, Schmid R, Preusser M, Paireder M, [Schoppmann SF](#), Haug A, Ba-Ssalamah A.
Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer
European Journal of Radiology 2016, 85 (3), pp. 540-545.
IF 2.843, Cited 14 times.
32. Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, Pfeiffer RM, [Schoppmann SF*](#), Cook MB*.
MicroRNA profiles of Barrett's esophagus and esophageal adenocarcinoma: Differences in glandular non-native epithelium
Cancer Epidemiology Biomarkers and Prevention 2016, 25 (3), pp. 429-437. Authors contributed equally last
IF 4.554, Cited 16 times.
33. Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, [Schoppmann SF](#), Ba-Ssalamah A.
Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer
European Radiology 2016, 26 (2), pp. 311-321.
IF 4.027, Cited 14 times.

34. Kristo I, [Schoppmann SF](#), Riegler M, Püspök A, Emmanuel K, Spaun G, Wrba F, Wenzl E, Schöfl R, Schreiber F, Häfner M, Madl C.
Austrian expert panel recommendation for radiofrequency ablation of Barrett's esophagus
European Surgery - Acta Chirurgica Austriaca 2015, 47 (6), pp. 319-323.
IF 0.349, Cited 4 times.
35. Schwarz C, Soliman T, Györi G, Silberhumer G, [Schoppmann SF](#), Mühlbacher F, Berlakovich GA.
Abdominal drainage after liver transplantation from deceased donors
Langenbeck's Archives of Surgery 2015, 400 (7), pp. 813-819.
IF 2.296, Cited 2 time.
36. Kristo I, Riegler FM, Asari R, Cosentini E, [Schoppmann SF](#).
Selected commentary to "Treatment of Barrett's esophagus with a novel focal cryoablation device: a safety and feasibility study"
European Surgery - Acta Chirurgica Austriaca 2015, 47 (5), pp. 274-278.
IF 0.349, Cited 1 time.
37. Zacherl J, Asari R, Fleischmann E, Karbon B, Rasoul-Rockenschaub S, Prager G, Riegler FM, [Schoppmann SF](#).
Fast-track Ivor Lewis esophageal resection
European Surgery - Acta Chirurgica Austriaca 2015, 47 (2), pp. 59-64.
IF 0.349, Cited 4 times.
38. Ilhan-Mutlu A, Starlinger P, Perkmann T, [Schoppmann SF](#), Preusser M, Birner P.
Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer
Biomarkers in Medicine 2015, 9 (4), pp. 327-335.
IF 2.346, Cited 14 times.
39. Dolak W, Mesteri I, Asari R, Preusser M, Tribl B, Wrba F, [Schoppmann SF](#), Hejna M, Trauner M, Hafner M, Püspök A
A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection
Endoscopy International Open 2015 ,3 (1), pp. E19-E28
IF no, Cited 4 times.
40. Zacherl J, Roy-Shapira A, Bonavina L, Bapaye A, Kiesslich R, [Schoppmann SF](#), Kessler WR, Selzer DJ, Broderick RC, Lehman GA, Horgan S.
Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial
Surgical Endoscopy 2015, 29 (1), pp. 220-229.
IF 3.117, Cited 53 times.
41. Ilhan-Mutlu A, Tezcan G, [Schoppmann SF](#), Preusser M, Spyridoula K, Karanikas G, Birner P.
MicroRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy
Cancer Investigation 2015, 33 (6), pp. 246-250.
IF 2.053, Cited 5 times.
42. Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, [Schoppmann SF](#), Tchormanov A, Streubel B, Tuettenberg J, Guentchev M.
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Cancer 2014, 120 (16), pp. 2440-2447.
IF 6.537, Cited 34 times.
43. Aumayr K, Soleiman A, Sahara K, Schindl M, Werba G, [Schoppmann SF](#), Birner P.
HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas
Applied Immunohistochemistry and Molecular Morphology 2014, 22 (2), pp. 146-152.
IF 2.042, Cited 19 times.
44. Mesteri I, [Schoppmann SF](#), Preusser M, Birner P.
Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma
European Journal of Cancer 2014, 50 (7), pp. 1354-1360.
IF 7.191, Cited 24 times.

45. Schwameis K, [Schoppmann SF](#), Stift J, Schwameis M, Stift A.
Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data
Oncology Letters 2014, 7 (5), pp. 1613-1617.
IF 1.664, Cited 9 times.

46. Jomrich G, Jesch B, Birner P, Schwameis K, Paireder M, Asari R, [Schoppmann SF](#).
Stromal expression of carbonic anhydrase IX in esophageal cancer
Clinical and Translational Oncology 2014, 16 (11), pp. 966-972.
IF2.392, Cited 17 times.

47. Schoppmann SF, Ricken G, Ilhan-Mutlu A, Nirtl N, Streubel B, Preusser M, Birner P.
Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors
Cancer Investigation 2014, 32 (7), pp. 363-367.
IF 2.053, Cited 2 times.

48. Schwameis K, Schwameis M, Zörner B, Lenglinger J, Asari R, Riegler FM, [Schoppmann SF](#).
Modern GERD treatment: Feasibility of minimally invasive esophageal sphincter augmentation
Anticancer Research 2014, 34 (5), pp. 2341-2348.
IF 1.865, Cited 26 times.

49. Mesteri I, Bayer G, Meyer J, Capper D, [Schoppmann SF](#), Von Deimling A, Birner P.
Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E
Modern Pathology 2014, 27 (1), pp. 135-144.
IF 6.655, Cited 44 times.

50. Koperek O, Aumayr K, Schindl M, Wrba F, Soleiman A, [Schoppmann SF](#), Sahora K, Birner P.
Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma
APMIS 2014, 122 (6), pp. 476-481.
IF 2.026, Cited 4 times.

51. Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, [Schoppmann SF](#), Petzelbauer P, von Deimling A, Berger W, Preusser M.
MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases
Archives of Dermatological Research 2014, 306 (10), pp. 873-884.
IF 2.148, Cited 3 times.

52. Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Telek B, Ba'Ssalamah A, Stift J, [Schoppmann SF](#), Gnant M.
A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
Anticancer Research 2014, 34 (5), pp. 2377-2384.
IF 1.865, Cited 21 times.

53. Kandioler D, [Schoppmann SF](#), Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kührer I, Hejna, M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J.
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study
Journal of Thoracic and Cardiovascular Surgery 2014, 148 (5), pp. 2280-2286.
IF 4.880, Cited 35 times.

54. [Schoppmann SF](#), Vinatzer U, Popitsch N, Mittlböck M, Liebmann-Reindl S, Jomrich G, Streubel B, Birner P.
Novel clinically relevant genes in gastrointestinal stromal tumors identified by exome sequencing
Clinical Cancer Research 2013, 19 (19), pp. 5329-5339.
IF 10.199, Cited 44 times.

55. Preusser M, Berghoff AS, Capper D, Von Deimling A, Maroske F, Brodowicz T, Hejna M, Birner P, [Schoppmann SF](#).
No evidence for BRAF-V600E mutations in gastroesophageal tumors: Results from a high-throughput analysis of 534 cases using a mutation-specific antibody
Applied Immunohistochemistry and Molecular Morphology 2013, 21 (5), pp. 426-430.
IF 2.042, Cited 8 times.
56. Schwameis K, Fochtman A, Schwameis M, Asari R, Schur S, Köstler W, Birner P, Ba-Ssalamah A, Zacherl J, Wrba F, Brodowicz T, [Schoppmann SF](#).
Surgical treatment of GIST - An institutional experience of a high-volume center
International Journal of Surgery 2013, 11 (9), pp. 801-806.
IF 2.693, Cited 21 times.
57. Ilhan-Mutlu A, Preusser M, [Schoppmann SF](#), Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Puspok A, Zacherl J, Hejna M.
Comparison between DCF (docetaxel, cisplatin and 5-fluorouracil) and modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract
Anticancer Research 2013, 33 (8), pp. 3455-3460.
IF 1.865, Cited 4 times.
58. [Schoppmann SF](#), Beer A, Nirtl N, Ba-Ssalamah A, Brodowicz T, Streubel B, Birner P.
Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway
Cancer Letters 2013, 335 (1), pp. 26-30.
IF 6.491, Cited 7 times.
59. [Schoppmann SF](#), Alidzanovic L, Schultheis A, Perkmann T, Brostjan C, Birner P.
Thrombocytes Correlate with Lymphangiogenesis in Human Esophageal Cancer and Mediate Growth of Lymphatic Endothelial Cells In Vitro
PLoS ONE 2013, 8 (6), art. no. e66941,
IF 2.766, Cited 9 times.
60. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, [Schoppmann SF](#), Zielinski CC, Streubel B, Birner P.
ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
Lung Cancer 2013, 80 (3), pp. 278-283.
IF 4.486, Cited 44 times.
61. [Schoppmann SF](#), Streubel B, Birner P.
Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer
European Journal of Cancer 2013, 49 (8), pp. 1876-1881.
IF 7.191, Cited 15 times.
62. Schwameis K, Ba-Ssalamah A, Wrba F, Birner P, Prager G, Hejna M, Schmid R, Asari R, Zacherl J, [Schoppmann SF](#).
The implementation of minimally-invasive esophagectomy does not impact short-term outcome in a high-volume center
Anticancer Research 2013, 33 (5), pp. 2085-2091.
IF 1.865, Cited 12 times
63. [Schoppmann SF](#), Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P.
Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer
Surgery (United States) 2013, 153 (4), pp. 526-534.
IF 3.574, Cited 51 times.
64. [Schoppmann SF](#), Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, Birner P.
Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus
Clinical and Experimental Metastasis 2013, 30 (4), pp. 441-446.
IF 3.455, Cited 65 times.
65. Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, [Schoppmann SF](#), Von Deimling A, Birner P.
Expression of BRAF V600E mutant protein in epithelial ovarian tumors
Applied Immunohistochemistry and Molecular Morphology 2013, 21 (2), pp. 159-164.
IF 2.042, Cited 32 times.

66. Pluschnig U, [Schoppmann SF](#), Preusser M, Datler P, Asari R, Ba-Ssalamah A, Schwameis K, Birner P, Zacherl J, Hejna M.
Modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma
Anticancer Research 2013, 33 (3), pp. 1035-1040.
IF 1.865, Cited 8 times.
67. Preusser M, Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi C, Hejna M, Capper D, Von Deimling A, [Schoppmann SF](#), Birner P.
Brain metastases of gastro-oesophageal cancer: Evaluation of molecules with relevance for targeted therapies
Anticancer Research 2013, 33 (3), pp. 1065-1072.
IF 1.865, Cited 16 times.
68. Bareck E, Ba-Ssalamah A, Brodowicz T, Eisterer W, Häfner M, Högenauer C, Kastner U, Kühr T, Längle F, Liegl-Atzwanger B, [Schoppmann SF](#),
Widmann G, Wrba F, Zacherl J, Ploner F.
Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria
Wiener Medizinische Wochenschrift 2013, 163 (5-6), pp. 137-152.
IF 0,836, Cited 14 times.
69. [Schoppmann SF](#), Langer FB, Prager G, Zacherl J.
Outcome and complications of long-term self-expanding esophageal stenting
Diseases of the Esophagus 2013, 26 (2), pp. 154-158.
IF 2.702, Cited 29 times.
70. Panhofer P, Springer C, Izay B, Grasl M, Burian M, [Schoppmann SF](#), Rath T, Jakesz R, Zacherl J.
Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngo-esophageal junction
Langenbeck's Archives of Surgery 2013, 398 (2), pp. 221-230.
IF 2.296, Cited 8 times.
71. Schindler A, Mozzanica F, Alfonsi E, Ginocchio D, Rieder E, Lenglinger J, [Schoppmann SF](#), Scharitzer M, Pokieser P, Kuribayashi S, Kawamura O,
Kusano M, Zelenik K.
Upper esophageal sphincter dysfunction: Diverticula-globus pharyngeus
Annals of the New York Academy of Sciences 2013, 1300 (1), pp. 250-260.
IF 4.277, Cited 10 times.
72. Mesteri I, Beller L, Fischer-See S, [Schoppmann SF](#), Lenglinger J, Wrba F, Riegler M, Zacherl J.
Radiofrequency ablation of Barrett's esophagus and early cancer within the background of the pathophysiology of the disease
European Surgery - Acta Chirurgica Austriaca 2012, 44 (6), pp. 366-382.
IF 0.349, Cited 10 times.
73. Pilat N, [Schoppmann SF](#), Stift J, Mazal P, Wekerle T, Berlakovich GA.
No evidence for recipient-derived hepatocytes in serial biopsies of sex-mismatched liver transplants
Transplantation 2012, 94 (9), pp. 953-957.
IF 3.960, Cited 7 times.
74. Mesteri I, Lenglinger J, Beller L, Fischer-See S, [Schoppmann SF](#), Wrba F, Riegler FM, Zacherl J.
Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy
European Surgery - Acta Chirurgica Austriaca 2012, 44 (5), pp. 304-313.
IF 0.349, Cited 9 times.
75. Birner P, Jesch B, Schultheis A, [Schoppmann SF](#).
RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases
Clinical and Experimental Metastasis 2012, 29 (6), pp. 551-559.
IF 3.455, Cited 29 times.
76. [Schoppmann SF](#), Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P.
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer
Clinical and Experimental Metastasis 2012, 29 (6), pp. 615-624.
IF 3.455 Cited 32 times.

77. [Schoppmann SE](#), Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, Birner P.
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer
Breast Cancer Research and Treatment 2012, 134 (1), pp. 237-244.
IF 3.605, Cited 68 times.
78. [Schoppmann SE](#), Berghoff AS, Jesch B, Zacherl J, Nirtl N, Jomrich G, Maroske F, Streubel B, Mesteri I, Birner P.
Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis
Future Oncology 2012, 8 (7), pp. 859-866.
IF 2.369, Cited 10 times.
79. Maresch J, [Schoppmann SE](#), Thallinger CMR, Zielinski CC, Hejna M.
Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment
Critical Reviews in Oncology/Hematology 2012, 82 (3), pp. 310-322.
IF 4.495, Cited 19 times.
80. Birner P, Schoppmann A, Schindl M, Dinhof C, Jesch B, Berghoff AS, [Schoppmann SE](#).
Human homologue for Caenorhabditis elegans CUL-4 protein overexpression is associated with malignant potential of epithelial ovarian tumours and poor outcome in carcinoma
Journal of Clinical Pathology 2012, 65 (6), pp. 507-511.
IF 2.894, Cited 31 times.
81. Birner P, Beer A, Vinatzer U, Stary S, Höftberger R, Nirtl N, Wrba F, Streubel B, [Schoppmann SE](#).
MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1
Clinical Cancer Research 2012, 18 (7), pp. 1879-1887.
IF 10.199, Cited 30 times.
82. Schoppmann A, Tamandl D, Herberger B, Längle F, Birner P, Geleff S, Grünberger T, [Schoppmann SE](#).
Comparison of lymphangiogenesis between primary colorectal cancer and corresponding liver metastases
Anticancer Research 2012, 31 (12), pp. 4605-4611.
IF 1.865, Cited 15 times.
83. Pertl L, Zacherl J, Mancusi G, Gächter JN, Asari R, [Schoppmann SE](#), Bigenzahn W, Schneider-Stickler B.
High risk of unilateral recurrent laryngeal nerve paralysis after esophagectomy using cervical anastomosis
European Archives of Oto-Rhino-Laryngology 2011, 268 (11), pp. 1605-1610.
IF 1.546, Cited 24 times.
84. Birner P, Jesch B, Friedrich J, Riegler M, Zacherl J, Hejna M, Wrba F, Schultheis A, [Schoppmann SE](#).
Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression
Annals of Surgical Oncology 2011, 18 (12), pp. 3330-3337.
IF 3.857, Cited 32 times.
85. Ba-Ssalamah A, Matzek W, Baroud S, Bastati N, Zacherl J, [Schoppmann SE](#), Hejna M, Wrba F, Weber M, Herold CJ, Gore RM.
Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results
European Radiology 2011, 21 (11), pp. 2326-2335.
IF 4.027, Cited 32 times.
86. [Schoppmann SE](#), Jesch B, Zacherl J, Wrba F, Hejna M, Maresch J, Langer FB, Riegler MF, Pluschnig U, Birner P.
HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases
British Journal of Surgery 2011, 98 (10), pp. 1408-1413.
IF 5.433, Cited 30 times.
87. Bojic M, Pluschnig U, Zacherl J, Thallinger CMR, Ba-Ssalamah A, Maresch J, Datler P, [Schoppmann SE](#), Hejna M.
Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: Experience at the Medical University of Vienna
Anticancer Research 2011, 31 (6), pp. 2379-2382.
IF 1.865, Cited 5 times.

88. Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C.
Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts
Disease Markers 2011, 31 (2), pp. 55-65.
IF 2.949, Cited 31 times.
89. Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C.
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and Anti-VEGF treatment
Neoplasia 2011, 13 (5), pp. 419-427.
IF 4.994, Cited 15 times.
90. Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C.
Discrimination between circulating endothelial cells and Blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in Cancer therapy
Neoplasia 2011, 13 (10), pp. 980-990.
IF 4.994, Cited 15 times.
91. [Schoppmann SF](#), Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P.
Expression of her-2 in carcinomas of the esophagus
American Journal of Surgical Pathology 2010, 34 (12), pp. 1868-1873.
IF 5.878, Cited 59 times.
92. Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C.
Thrombospondin-1: A unique marker to identify in vitro platelet activation when monitoring in vivo processes
Journal of Thrombosis and Haemostasis 2010, 8 (8), pp. 1809-1819.
IF 4.899, Cited 37 times.
93. Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, [Schoppmann SF](#), Zacherl J, Prager G.
Conversion from sleeve gastrectomy to roux-en-y gastric bypass-indications and outcome
Obesity Surgery 2010, 20 (7), pp. 835-840.
IF 3.890, Cited 132 times.
94. Langer FB, Shakeri-Leidenmühler S, Bohdjalian A, [Schoppmann SF](#), Zacherl J, Felberbauer FX, Vila G, Prager G.
Strategies for weight regain after sleeve gastrectomy
Surgical Laparoscopy, Endoscopy and Percutaneous Techniques 2010, 20 (3), pp. 159-161.
IF 0.986, Cited 17 times.
95. Langer FB, [Schoppmann SF](#), Prager G, Riegler FM, Zacherl J.
Solving the Problem of Difficult Stent Removal Due to Tissue Ingrowth in Partially Uncovered Esophageal Self-Expanding Metal Stents
Annals of Thoracic Surgery 2010, 89 (5), pp. 1691-1692.
IF 3.780, Cited 21 times.
96. Langer FB, [Schoppmann SF](#), Prager G, Tomaselli F, Pluschnig U, Hejna M, Schmid R, Zacherl J.
Temporary placement of self-expanding oesophageal stents as bridging for neo-adjuvant therapy
Annals of Surgical Oncology 2010, 17 (2), pp. 470-475.
IF 3.857, Cited 59 times.
97. [Schoppmann SF](#), Prager G, Langer FB, Riegler FM, Kabon B, Fleischmann E, Zacherl J.
Open versus minimally invasive esophagectomy: A single-center case controlled study
Surgical Endoscopy 2010, 24 (12), pp. 3044-3053.
IF 3.117, Cited 110 times.
98. Panhofer P, Izay B, Schwameis K, [Schoppmann SF](#), Prager G, Jakesz R, Riegler FM, Zacherl J.
Gastrointestinal reconstructions in 1200 patients with cancer at the pharyngoesophageal junction
European Surgery - Acta Chirurgica Austriaca 2010, 42 (1), pp. 38-48.
IF 0.349, Cited 3 times.

99. [Schoppmann SF](#), Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P.
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
Annals of Oncology 2009, 21 (5), pp. 955-960.
IF 13.930 Cited 59 times.
100. Silberhumer GR, Györi G, Burghuber C, Neumayer C, Riegler M, Jakesz R, Prager G, [Schoppmann SF](#), Zacherl J.
The value of protecting the longitudinal staple line with invaginating sutures during esophageal reconstruction by gastric tube pull-up
Digestive Surgery 2009, 26 (4), pp. 337-341.
IF 2.031, Cited 20 times.
101. [Schoppmann SF](#), Prager G, Langer F, Riegler M, Fleischman E, Zacherl J.
Fifty-five minimally invasive esophagectomies: A single centre experience
Anticancer Research 2009, 29 (7), pp. 2719-2725.
IF 1.865, Cited 32 times.
102. Silberhumer GR, Hufschmid M, Wrba F, Gyoeri G, [Schoppmann SF](#), Tribl B, Wenzl E, Prager G, Laengle F, Zacherl J.
Surgery for gastrointestinal stromal tumors of the stomach
Journal of Gastrointestinal Surgery 2009, 13 (7), pp. 1213-1219.
IF 2.813, Cited 68 times.
103. Blaha P, Exner R, Dal Borgo A, Bigenzahn S, Panhofer P, Riedl O, [Schoppmann SF](#), Bachleitner-Hofmann T, Sporn E, Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M.
Is endocrine therapy really pleasant? considerations about the long-term use of antihormonal therapy and its benefit/side effect ratio
Breast Care 2009, 4 (3), pp. 155-161.
IF 2.028, Cited 3 times.
104. Gnant M, Dubsky P, Fitzal F, Blaha P, [Schoppmann SF](#), Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R.
Maintaining bone density in patients undergoing treatment for breast cancer: Is there an adjuvant benefit?
Clinical Breast Cancer 2009, 9 (SUPPL.1), pp. S18-S27.
IF 2.703, Cited 14 times.
105. Kappel S, Bichler C, Wolf B, Gacic S, [Schoppmann SF](#), Devyatko Y, Prager G, Ba-SSalah A, Wrba F, Pluschnig U, Kühner I, Mittlböck M, Hejna M, Zacherl J, Kandioler D, Zacherl J.
Turning the tables on surgical oncology: The • Pancho trial unplugged
European Surgery - Acta Chirurgica Austriaca 2008, 40 (6), pp. 277-283.
IF 0.349, Cited 7 times.
106. Tamandl D, Herberger B, Gruenberger B, [Schoppmann SF](#), Puhalla H, Schindl M, Schima W, Jakesz R, Gruenberger T.
Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases
Surgery 2008, 143 (5), pp. 648-657.
IF 3.574, Cited 35 times.
107. Schindl M, Gnant M, [Schoppmann SF](#), Horvat R, Birner P.
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer
Anticancer Research 2007, 27 (2), pp. 949-952.
IF 1.865, Cited 55 times.
108. Tamandl D, Gruenberger B, Herberger B, [Schoppmann SF](#), Bodingbauer M, Schindl M, Puhalla H, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T.
Selective resection of colorectal liver metastases
European Journal of Surgical Oncology 2007, 33 (2), pp. 174-182.
IF 3.688, Cited 47 times.

109. [Schoppmann SF](#), Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P. **Hypoxia inducible factor-1 α correlates with VEGF-C expression and lymphangiogenesis in breast cancer** Breast Cancer Research and Treatment 2006, 99 (2), pp. 135-141. IF 2.028, Cited 131 times.
110. [Schoppmann SF](#), Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P. **VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival** Surgery 2006, 139 (6), pp. 839-846. IF 3.574, Cited 170 times.
111. Fenzl A, [Schoppmann SF](#), Geleff S, Birner P, Wrba F, Herberger B, Teleky B, Herbst F, Kührer I, Jakesz R, Längle F. **Vascular endothelial growth factor-C expression and lymphangiogenesis in colorectal cancer** European Surgery - Acta Chirurgica Austriaca 2006, 38 (2), pp. 149-154. IF 0.349, Cited 5 times.
112. Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsy P, Hayden H, [Schoppmann SF](#), Pfragner R, Gnant M, Friedl J, Stift A. **Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma** Journal of Clinical Endocrinology and Metabolism 2006, 91 (11), pp. 4571-4577. IF 5.789, Cited 32 times.
113. [Schoppmann SF](#), Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R. **Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer** Annals of Surgery 2004, 240 (2), pp. 306-312. IF 9.203, Cited 326 times.
114. [Schoppmann SF](#), Soleiman A, Kalt R, Okubo Y, Benisch C, Nagavarapu U, Herron GS, Geleff S. **Telomerase-immortalized lymphatic and blood vessel endothelial cells are functionally stable and retain their lineage specificity** Microcirculation 2004, 11 (3), pp. 261-269. IF 2.797, Cited 29 times.
115. Valencak J, Heere-Ress E, Kopp T, [Schoppmann SF](#), Kittler H, Pehamberger H. **Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma** European Journal of Cancer 2004, 40 (3), pp. 358-364. IF 7.191, Cited 78 times.
116. [Schoppmann SF](#), Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P. **Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer** International Journal of Cancer 2004, 104 (6), pp. 677-682. IF 7.360, Cited 193 times.
117. Geleff S, [Schoppmann SF](#), Oberhuber G. **Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease** Virchows Archiv 2003, 442 (3), pp. 231-237. IF 2,848, Cited 74 times.
118. Schindl M*, [Schoppmann SF*](#), Ströbel T, Heinzl H, Leisser C, Horvat R, Birner P. **Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors** Clinical Cancer Research 2003, 9 (2), pp. 779-785. IF 10.199, Cited 183 times. * contributed equally first author
119. [Schoppmann SF](#), Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Nagy K, Alitalo K, Kerjaschki D. **Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis** American Journal of Pathology 2002, 161 (3), art. no. 64255, pp. 947-956. IF 4.069, Cited 842 times.

120. Schindl M, [Schoppmann SF](#), Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber
Overexpression of hypoxia-inducible factor 1 α is associated with an unfavorable prognosis in lymph node-positive breast cancer
Clinical Cancer Research 2002, 8 (6), pp. 1831-1837.
IF 10.199, Cited 468 times.
121. [Schoppmann SF](#), Schindl M, Breiteneder-Geleff S, Soleiman A, Breitenecker G, Karner B, Birner P.
Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervical cancer
Anticancer Research 2001, 21 (5), pp. 3419-3423.
IF 1.865, Cited 49 times.
122. [Schoppmann SF](#), Birner P, Studer P, Breiteneder-Geleff S.
Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer
Anticancer Research 2001, 21 (4 A), pp. 2351-2355.
IF 1.865, Cited 187 times.
123. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, [Schoppmann SF](#), Stingl G, Kerjaschki D, Maurer D.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages
Journal of Experimental Medicine 2001, 194 (6), pp. 797-808.
IF 10.790, Cited 543 times.
124. Schindl M, Oberhuber G, Obermair A, [Schoppmann SF](#), Karner B, Birner P.
Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer
Cancer Research 2001, 61 (15), pp. 5703-5706.
IF 9.130, Cited 218 times.

3.3.2 Publications in peer-reviewed Journals (Reviews, Meeting Abstracts, Comments and Guidelines) (IF taken from Journal Citation Reports, Thomson Reuters 2017)

1. [Schoppmann SF](#), Kristo I, Riegler M.
Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?
Translational Gastroenterology and Hepatology 2018, 3 (December), art. no. 101,
Cited 1 time.
2. Rieder E, Riegler M, Simić AP, Skrobić OM, Bonavina L, Gursk, R, Paireder M, Castell DO, [Schoppmann SF](#).
Alternative therapies for GERD: A way to personalized antireflux surgery
Annals of the New York Academy of Sciences 2018, Dec;1434(1):360-369.
IF 4.277, Cited 3 times.
3. Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Gnant M, [Schoppmann SF](#).
Elevated Mean Corpuscular Volume Predicts Poor Outcome in Patients With Adenocarcinomas of the Esophago-gastric Junction
Journal of the American College of Surgeons 2018, 227 (4), pp. E215-E215
IF 4.767
4. Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Gnant M, [Schoppmann SF](#).
No Difference of the Systemic Immune-Inflammation Index as Prognostic Factor for Patients with Adenocarcinoma of the Gastroesophageal Junction With or Without Neoadjuvant Treatment
Journal of the American College of Surgeons 2018, 227 (4), pp. S245-S246
IF 4.767
5. Labenz J, Thattamparambil P, Gutt C, Nieponice A, Menke V, Madisch A, Weise R, [Schoppmann SF](#), Pedersen JB, Eypasch EP, Benedix F, Bouvy ND, Hesselbarth N.
Interim results of a prospective multi-center registry of lower esophageal sphincter stimulation of GERD: the lessgerd registry
Gastroenterology 2018, Meeting Abstract 443, 154 (4) pp: S101-S101
IF 20.773, Cited 2 times.
6. Chang Y, Ignatova D, Kollmann, D, Schweiger T, Schwarz S, Lewik G, [Schoppmann SF](#), Hoetzenecker W, French LE, Klepetko W, Hoetzenecker K, Guenova E.
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Journal of investigative Dermatology 2018, Meeting Abstract 494, 138 (5) pp: S84-S84
IF 6.448
7. Ignatova D, Kollmann D, Jedamzik J, Chang Y, Jomrich G, Baierl A, Kazakov D, Michal M, Hoetzenecker W, Schatton T, French LE, Asari R, Preusser M, Gnant M, [Schoppmann SF*](#), Guenova E. *.
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Journal of investigative Dermatology 2018, Meeting Abstract 595, 138 (5), pp. S101-S101, *equally last author
IF 6.448
8. Gruber ES, Birner P, Merkel O, Bergmann MM, [Schoppmann SF](#), Park J, Moriggl R, Tse W, Kenner L.
The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients
Cancer Research 2017, Meeting Abstract 4463, 77 (Supp. 13)
IF 9.130

9. Riegler M, Kristo I, Nikolic M, Rieder E, [Schoppmann SF](#).
Update on the management of Barrett's esophagus in Austria
 European Surgery - Acta Chirurgica Austriaca 2017, 49 (6), pp. 282-287.
 IF 0.349, Cited 5 times.

10. Riegler M, Kristo I, Asari R, Rieder E, [Schoppmann SF](#).
Dietary sugar and Barrett's esophagus
 European Surgery - Acta Chirurgica Austriaca 2017, 49 (6), pp. 279-281.
 IF 0.349, Cited 3 time.

11. Rieder E, Asari R, Paireder M, Preuser M, Birner P, [Schoppmann SF](#).
Immediate Surgery and Not Preoperative Chemotherapy Improves Recurrence-Free Interval in Patients With cT2 Esophageal Cancer
 Gastroenterology 2016, Meeting Abstract Tu1275, 150 (4) pp. S1249-S1249
 IF 20.773

12. Jomrich G, [Schoppmann SF](#).
Targeted therapy in gastric cancer
 European Surgery - Acta Chirurgica Austriaca 2016, 48 (5), pp. 278-284.
 IF 0.349, Cited 15 times.

13. Jomrich G, [Schoppmann SF](#).
Targeting HER 2 and angiogenesis in gastric cancer
 Expert Review of Anticancer Therapy 2016, 16 (1), pp. 111-122.
 IF 2.347, Cited 10 times.

14. Kristo I, Riegler M, [Schoppmann SF](#).
Should antireflux surgery be considered after successful endoscopic treatment of Barrett's esophagus with dysplasia and early cancer?
 Endoscopy 2016, 48 (1), p. 92.
 IF 6.629, Cited 2 time.

15. Lenglinger J, Riegler M, [Schoppmann SF](#).
Barrett's esophagus and antireflux surgery: Wraps, rings, and HALOs
 Annals of Surgery 2015, 261 (2), p. e49.
 IF 9.203

16. Ilhan-Mutlu A, Starlinger P, Perkmann T, [Schoppmann SF](#), Preusser M, Birner P.
Erratum : Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer
 Biomarkers in Medicine 2015, 9 (6), p. 617.
 IF 2.346

17. Rieder E, Lenglinger J, Spaun GO, Mari S, Asari R, Swanstrom LL, [Schoppmann SF](#).
Implementation of PerOral Endoscopic Myotomy (POEM) and Prolonged Dilatation As Treatment for Achalasia: Is It Worth the Cost?
 Gastrointestinal Endoscopy 2015, Meeting Abstract: Tu1510, 81 (5), pp. AB490-AB491
 IF 7.204

18. Lenglinger J, Kristo I, Scharitzer M, Rieder E, [Schoppmann SF](#).
Lower Esophageal Sphincter Dilation Using a Balloon Incorporating Impedance Planimetry Imaging (Esoflip (R)): Feasibility and Initial Experience in the Treatment of Patients With Achalasia
 Gastroenterology 2015, Meeting Abstract: Tu1154, 148 (4), pp: S805-S805, Supp. 1
 IF 20.773, Cited 1 time.

19. Lenglinger J, Rieder E, Scharitzer M, Kristo I, [Schoppmann SF](#).
Impedance Planimetry (EndoFLIP (R)) Measurements at the Esophago-Gastric Junction Distinguish Neuromuscular Disorders From Fibrotic Lesions in Dysphagia Patients
 Gastroenterology 2015, Meeting Abstract: Tu1153, 148 (4), pp: S805-S805, Supp. 1
 IF 20.773

20. Kristo I, Riegler M, [Schoppmann SF](#).
Laryngopharyngeal reflux COPD to uncover reflux and columnar lined esophagus
 International Journal of COPD 2015, 10 (1), pp. 2095-2096.
 IF 2.917, Cited 1 time.

21. Kristo I, [Schoppmann SF](#).
Diagnosis and treatment of benign inflammatory esophageal diseases
 European Surgery - Acta Chirurgica Austriaca 2015, 47 (4), pp. 188-198.
 IF 0.349, Cited 7 times.

22. Kristo I, Asari R, Rieder E, Riegler M, [Schoppmann SF](#).
Treatment of Barrett's esophagus: Update on new endoscopic surgical modalities
 Minerva Chirurgica 2015, 70 (2), pp. 107-118.
 IF 0.554, Cited 8 times.

23. Riegler M, Schwameis K, Asari R, [Schoppmann SF](#).
Otolaryngeal GERD symptoms and barrett esophagus: Implications for cancer prevention
 Journal of Clinical Gastroenterology 2014, 48 (2), p. 191.
 IF 2.968, Cited 1 time.

24. [Schoppmann SF](#).
Surgical controversies in esophageal cancer
 Memo - Magazine of European Medical Oncology 2014, 7 (1), pp. 30-33.
 Cited 11 times.

25. Riegler M, [Schoppmann SF](#).
Selected commentary to "Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia. A randomized clinical trial"
 European Surgery - Acta Chirurgica Austriaca 2014, 46 (3), pp. 133-136.
 IF 0.349, Cited 1 times.

26. Riegler M, Asari R, [Schoppmann SF](#).
Face Barrett's: Esophageal Adenocarcinoma Affects the Young
 Journal of Gastrointestinal Surgery 2014, 18 (4), pp. 882-883.
 IF 2.813, Cited 1 time.

27. Riegler M, Asari R, Cosentini EP, Wrba F, [Schoppmann SF](#).
Critical assessment of a new endoscopic anatomic concept for the so-called cardia in the sense of the notions of parmenides and martin heidegger Zeitschrift fur Gastroenterologie 2014, 52 (4), pp. 367-373.
 IF 1.612, Cited 6 times.
28. Schwarz C, Soliman T, Gyori G, Silberhumer G, [Schoppmann SF](#), Muhlbacher F, Berlakovich GA.
To drain or not to drain after liver transplantation
 Transplant International 2014, Meeting Abstract: EP-23, 27 (SI) pp. 19-20, Supp. 2
 IF 3.196
29. Rieder E, Asari R, Lenglinger J, [Schoppmann SF](#).
Endolumenal Stent Suture-Fixation Compared to Endoscopic Clips for Prevention of Esophageal Stent Migration During Prolonged Dilatation in Recurrent Achalasia
 Gastroenterology 2014, Meeting Abstract: Su1806, 146 (5), pp. S1041-S1041, Supp. 1
 IF 20.773, Cited 2 times.
30. Pilat N, [Schoppmann SF](#), Mazal P, Stift J, Wekerle T, Berlakovich GA.
Serial Biopsies of Sex-Mismatched Liver Transplants Show No Evidence for Recipient-Derived Hepatocytes
 Transplantation 2014, Meeting Abstract: 1992, 94 (10), pp. 225-225, Supp. S
 IF 3.960
31. Roy-Shapira A, Bapaye A, Kiesslich R, Horgan S, [Schoppmann SF](#), Zacherl J, Bonavina L, Lehman GA.
Effective Endoscopic Treatment of Gastroesophageal Reflux Disease Using a New Endoscopic Stapling System Results of a Prospective Controlled Multicenter Trial
 Gastroenterology 2014, 142 (5), pp. S1076-S1076, Supp.1
 IF 20.773, Cited 1 time
32. Asari R, Riegler M, [Schoppmann SF](#).
Dilated distal esophagus: Optimal position for magnetic sphincter augmentation
 Journal of the American College of Surgeons 2013, 217 (6), pp. 1155-1156.
 IF 4.767, Cited 1 time.
33. Lenglinger J, See SF, Beller L, Cosentini EP, Asari R, Wrba F, Riegler M, [Schoppmann SF](#).
Review on novel concepts of columnar lined esophagus
 Wiener Klinische Wochenschrift 2013, 125 (19-20), pp. 577-590.
 IF 1.003, Cited 6 times.
34. Asari R, Riegler M, [Schoppmann SF](#).
Extending Barrett's esophagus cancer risk profile towards genetic abnormalities
 Molecular Cytogenetics 2013, 6 (1), art. no. 10, .
 IF 1.167, Cited 1 time.

35. Schoppmann SF, Asari R, Riegler M.
Barrett's esophagus as a marker for increased risk for esophageal cancer and cardiorespiratory disease
 Endoscopy 2013, 45 (2), p. 152.
 IF 6.629, Cited 3 time.
36. Lenglinger J, See SF, Beller L, Cosentini E, Asari R, Wrba F, Riegler M, Schoppmann SF.
The cardia: esophageal or gastric? Critical reviewing the anatomy and histopathology of the esophagogastric junction.
 Acta chirurgica lugoslavica 2012, 59 (3), pp. 15-26.
 Cited 4 times.
37. Lenglinger J, Riegler M, Cosentini E, Asari R, Mesteri I, Wrba F, Schoppmann SF.
Review on the annual cancer risk of Barrett's esophagus in persons with symptoms of gastroesophageal reflux disease
 Anticancer Research 2012, 32 (12), pp. 5465-5474.
 IF 1.865, Cited 15 times.
38. Schoppmann SF, Riegler MF.
Radial esophageal acid exposure and the dilated distal esophagus
 Journal of Gastroenterology 2012, 47 (11), pp. 1275-1276.
 IF 5.561
39. Lenglinger J, Riegler M, Schoppmann SF.
Gastroesophageal reflux disease and metabolic syndrome
 Internal Medicine 2012, 51 (20), p. 2993.
 IF 0.817, Cited 1 time.
40. Lenglinger J, Riegler M, Schoppmann SF.
Letter: Cancer risk among persons with columnar-lined oesophagus
 Alimentary Pharmacology and Therapeutics 2012, 36 (6), p. 599.
 IF 7.357, Cited 1 time.
41. Schoppmann SF, Azari R, Riegler FM.
Selected commentary to "incidence of adenocarcinoma among patients with Barrett's esophagus"
 European Surgery - Acta Chirurgica Austriaca 2012, 44 (4), pp. 291-295.
 IF 0.349
42. Pilat N, Mazal P, Stift J, Schoppmann SF, Wekerle T, Berlakovich GA.
No Evidence for Recipient-Derived Hepatocytes in Serial Biopsies of Sex-Mismatched Liver Transplants.
 American Journal of Transplantation 2012, Meeting Abstract: 922 ,12(SI), pp. 297-297 Supp. 3
 IF 6.493
43. Schwarz C, Schoppmann SF, Gyori G, Silberhumer G, Soliman T, Steininger R, Muhlbacher F, Berlakovich G.
To Drain or Not To Drain after Liver Transplantation
 Liver Transplantation 2012, 18, pp. S271-S271, Supp. 1
 IF 3.756

44. Birner P, [Schoppmann SF](#).
Her-2 in gastroesophageal cancer: Pathobiology, diagnostic and therapeutic implications
 European Surgery - Acta Chirurgica Austriaca 2011, 43 (3), pp. 162-167.
 IF 0.349, Cited 3 times.
45. Birner P, Jesch B, [Schoppmann SF](#).
Her-2 in carcinomas of the esophagus and its metastases
 Virchows Archiv 2011, 459, pp. S15-S15, Supp. 1
 IF 2.936
46. Brostjan C, Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M.
The role of myelosuppression in synergy between chemotherapy and anti-VEGF treatment
 Journal of Clinical Oncology 2011, Meeting Abstract: e13527, 29 (15), Supp. S
 IF 26.360
47. Pluschnig U, Zacherl J, [Schoppmann SF](#), Raderer M, Prager G, Bartsch R, Ba-Ssalamah A, Lamm W, Zielinski C, Hejna M.
Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX)
 Journal of Clinical Oncology 2011, Meeting Abstract: 136, 29 (4), Supp. S
 IF 26.360
48. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, [Schoppmann SF](#), Stingl G, Kerjaschki D, Maurer D.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages
 Journal of Investigative Dermatology 2011, Meeting Abstract: 013117 (6), pp. 1680-1680
 IF 6.448
49. Pluschnig U, Zacherl J, [Schoppmann SF](#), Raderer M, Prager G, Bartsch R, Ba-Ssalamah A, Lamm W, Zielinski C, Hejna M.
Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis
 Journal of Clinical Oncology 2010, Meeting Abstract: e14682, 28 (15), Supp. S
 IF 26.360
50. Starlinger P, Nemeth C, [Schoppmann SF](#), Kuehrer I, Gnant M, Gruenberger B, Gruenberger T, Brostjan C.
Monitoring of Angiogenic Factors Cannot Replace Tumor Marker Analysis in Bevacizumab-Based Cancer Therapy
 Gastroenterology 2009, 136 (5), pp. A746-A746 Supp.1 Published:
 IF 20.773
51. [Schoppmann SF](#), Bareck E, Längle F, Zacherl J.
Gastrointestinal stromal tumors [Gastrointestinale Stromatumoren]
 Journal für Gastroenterologische und Hepatologische Erkrankungen 2009, 7 (4), pp. 45-52.
52. Zacherl J, [Schoppmann SF](#), Prager G, Lenglinger J, Eisler M, Cosentini EP, Miholic J, Riegler FM.
Endoscopic surgery for the treatment of achalasia [Endoskopische Chirurgie zur Behandlung der Achalasie]
 Minimal Invasive Chirurgie 2008, 17 (4), pp. 205-208.

53. Gnant M, Schoppmann SF, Kuehrer I, Goetzinger P, Sahara K, Kandutsch S, Wrba F, Brostjan C, Goetzinger P, Turetschek K, Zielinski C, Teleky B, Friedl J, Stift A, Jakesz R.

Bevacizumab plus gemcitabine for the neoadjuvant treatment of locally advanced non-metastatic pancreatic cancer

Annals of Oncology 2008, 19, pp.70-71 Supp. 6
IF 13.930

54. Schima W, Schoppmann SF, Prager G.

Acute abdomen after laparoscopic cholecystectomy [Akutes abdomen nach laparoskopischer cholezystektomie]

Journal fur Gastroenterologische und Hepatologische Erkrankungen 2007, 5 (3), p. 20.

55. Schoppmann SF, Jakesz R.

Early-stage breast cancer - Highlights at ASCO 2006

Breast Care 2006, 1 (4), pp. 265-269.
IF 2.028

56. Bachleitner-Hofmann T, Schoppmann SF, Rudas M, Birner P, Wiener H, Dubsky P, Blaha P, Sporn E, Panhofer P, Fitzal F, Roka S, Kandioler D, Gnant M, Jakesz R.

A case of phyllodes tumor with focal transition into low-grade lymphangiosarcoma

Breast Care 2006, 1 (6), pp. 391-394.
IF 2.028

57. Tamandl D, Gruenberger B, Herberger B, Schoppmann SF, Bodingbauer M, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T.

Safe surgery for colorectal cancer liver metastases using modern dissection techniques

Annals of Oncology 2006, 17, pp. 57-57. Supp. 6
IF 13.930

58. Schoppmann SF, Fenzl A, Tamandl D, Bodingbauer M, Schindl M, Puhalla H, Grunberger B, Teleky B, Grunberger T, Langle F.

Impact of lymphangiogenesis in colorectal liver metastases

Annals of Oncology 2006, 17, pp: 33-33, Supp. 6
IF 13.930

59. Schoppmann SF.

Lymphangiogenesis, inflammation and metastasis

Anticancer Research 2005, 25 (6 C), pp. 4503-4511.
IF 1.865, Cited 42 times

60. Schoppmann SF, Fenzl A, Laengle F.

Surgical oncology: Impact of lymphangiogenesis for metastasis formation

European Surgery - Acta Chirurgica Austriaca 2005, 37 (3), pp. 153-158.
IF 0.349, Cited 3 times.

61. Schoppmann SF, Horvat R, Birner P.
Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review)
Oncology Reports 2002, 9 (3), pp. 455-460.
IF 2.976, Cited 80 times

3.3.3 Book Chapters as Chapterauthor or Editor

Schoppmann SF, (Hrsg.), Riegler M

Multidisciplinary Management of Gastroesophageal Reflux Disease

Springer – Book 395065 – in press

Chirurgie benigner Ösophaguserkrankungen (1. Auflage) Gockel (Hrsg.)

Schoppmann SF: **Minimal-invasive Chirurgie gutartiger Tumoren des Ösophagus**

Springer in press

Schoppmann SF, Kristo I, Riegler M.

Innovations in minimally invasive therapy of GERD

Surgery for Benign Oesophageal Disorders 2017, pp. 35-54.

Kristo I, Riegler M, Schoppmann SF.

Endoscopic therapy for barrett's esophagus: Who and how?

Surgery for Benign Oesophageal Disorders 2017, pp. 105-132.

Devyatko E, Schoppmann SF, Zacherl J.

Resection of Benign Tumors

Minimally Invasive Thoracic and Cardiac Surgery (ed. R. Inderbitzi)

Book Chapter, pp. 329-339

Riegler M, Fischer See S, Schoppmann SF, Zacherl J.

Radiofrequency ablation and anti reflux management for non-dysplastic barrett's esophagus

Innovation in Esophageal Surgery 2012, pp. 27-41.

Book Chapter, Cited 1 time.

Therapiemanagement Lebermetastasen bei Gastrointestinalen Tumoren

Schoppmann SF: **Lebermetastasen bei Magen – Ösophaguskarzinomen**

Unimed Verlag AG, Bremen – London – Boston, 2008